Key Highlights

  • Pro Medicus has signed a 5-year, A$16 million contract renewal with The Ohio State University Wexner Medical Center (OSUWMC), including the addition of Visage 7 Workflow and Visage 7 Cardiology Imaging modules to the existing enterprise imaging platform.
  • The OSUWMC renewal brings total contract renewals for FY26 to A$141 million — a figure that management highlights as maintaining the Company's track record of near-total client retention across its installed base of major academic medical centres and health systems.
  • Pro Medicus shares gained 1.48% to AUD 162.00 on June 4, 2026, a measured appreciation on a stock that has compounded substantially over recent years and now trades at a price that fully reflects a premium-quality, high-retention healthcare software Business.

 

Pro Medicus (ASX:PME) traded at AUD 162.00 on June 4, 2026, gaining AUD 2.37 or 1.48% on the day. The stock's absolute price level — at AUD 162, one of the higher absolute prices among ASX technology companies — reflects years of consistent contract growth, high-Margin Revenue, and a demonstrably Capital-efficient business model. The 1.48% gain on a contract renewal announcement is consistent with the Company's established pattern: individual contract wins are regularly material but rarely move the needle dramatically on a stock already priced for continued execution. The market's focus for Pro Medicus is cumulative contract momentum, which the A$141 million in FY26 renewals meaningfully advances.

Ohio State University Wexner Medical Center: Client Profile

OSUWMC is a substantial academic medical centre and teaching hospital operating six hospitals with over 1,400 inpatient beds, approximately 22,000 staff and 2,000 physicians. As the teaching hospital for The Ohio State University College of Medicine, it combines the imaging Volume of a large tertiary hospital with the clinical research requirements of an academic institution. This profile — high volume, diverse imaging modalities, demanding workflow requirements — represents the exact client profile for which Visage 7's enterprise imaging platform is optimised.

The renewal at increased minimums and an increased fee per transaction is analytically important. It confirms that OSUWMC has not only retained the platform but has agreed to higher contractual floors and unit Economics on renewal — an indicator of pricing power and the degree to which Visage 7 is embedded in clinical operations.

Module Expansion: Workflow and Cardiology Imaging

Beyond the base renewal, OSUWMC has added Visage 7 Workflow and Visage 7 Cardiology Imaging to its deployment. This module expansion is a recurring feature of Pro Medicus's renewal strategy: existing clients, having embedded Visage 7 as their core radiology platform, progressively adopt additional modules that replace legacy point solutions. Each new module extends the revenue per client, deepens the integration footprint, and raises the effective switching cost for a future procurement cycle.

Cardiology imaging is a strategically significant module addition. Cardiology departments have historically maintained separate imaging IT infrastructure from radiology — typically older PACS systems from vendors specialising in cardiovascular imaging. Visage 7's ability to extend natively into cardiology represents a direct expansion of the addressable revenue pool from existing clients and positions the platform as a true enterprise imaging solution rather than a radiology-specific tool.

A$141 Million in FY26 Renewals: The Retention Metric

Management's disclosure that the OSUWMC renewal brings total FY26 renewals to A$141 million is the most analytically significant data point in the announcement. Pro Medicus's transaction-based revenue model means that each renewed contract commits the client to a minimum annual payment — typically with volume-based upside — over a multi-year term. An accumulated A$141 million in FY26 renewals represents contracted minimum revenue that will flow through the income statement over the respective contract terms.

The sustained accumulation of renewals at increased minimums and per-transaction fees demonstrates that Pro Medicus is not merely retaining its client base but systematically repricing it upward on each renewal cycle. This dynamic — organic revenue growth from within the existing installed base without requiring new client Acquisition — is a characteristic of software businesses with demonstrably superior products in markets where switching costs are high and user satisfaction is deep.

Transaction-Based Model and Revenue Upside

Pro Medicus's transaction-based commercial model means that contracted minimums represent a floor rather than a ceiling. Clients pay per imaging study processed through Visage 7, and growth in imaging volumes at a hospital — driven by demographic trends, expanding clinical indications and increased diagnostic utilisation — translates directly into revenue above minimum contracted levels. This creates an embedded organic growth mechanism that amplifies the base revenue trajectory without requiring incremental selling effort at established clients.

Conclusion

Pro Medicus's Ohio State University contract renewal is the latest evidence of what has become a consistent execution pattern: multi-year renewals at major academic medical centres, negotiated at higher minimum commitments and unit economics, with module expansion adding incremental revenue without new client acquisition cost. The A$141 million in FY26 renewals affirms the depth of Visage 7's clinical and operational integration across its installed base. The 1.48% share price gain on June 4 reflects measured market approval for a company that is executing precisely as expected — and at a stock price that has already absorbed considerable expectation of continued excellence.